IKT Inhibikase Therapeutics, Inc.
Healthcare$1.70+0.59%ClosedMarket Cap: $120.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.99
P/S
0.00
EV/EBITDA
-1.26
DCF Value
$1.41
FCF Yield
-30.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-41.3%
ROA
-29.4%
ROIC
-33.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-18.2M | $-16.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-13.8M | $-12.7M | $— | — |
| FY null | $0.00 | NaN% | $-52.0M | $-48.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-12.8M | $-11.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.8M | $-9.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.6M | $-13.7M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-12.9M | $-12.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-28.6M | $-27.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-5.8M | $-5.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-5.1M | $-5.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-4.8M | $-4.6M | $— | — |
| Q4 2023 | $1.00 | -656700.0% | $-4.4M | $-4.2M | $-0.68 | — |